Get started
Author

Emma L. Jenkins

Observed names: Emma Jenkins, Emma-Louise Jenkins, Jenkins, Emma
ORCID: 0000-0001-5860-8762
Observed ORCID: 0000-0001-5860-8762
OpenAlex ID: A5014643231
Inhibition of Arp2/3-mediated actin polymerization by PICK1 regulates neuronal morphology and AMPA receptor endocytosis
2008 · Daniel L. Rocca, Stéphane Martin, et al. · Nature Cell Biology · 238
Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
2015 · Barry R. Davies, Nin Guan, et al. · Molecular Cancer Therapeutics · 76
Transcriptomic analysis of patients with tetralogy of Fallot reveals the effect of chronic hypoxia on myocardial gene expression
2010 · Mohamed T. Ghorbel, Myriam Cherif, et al. · Journal of Thoracic and Cardiovascular Surgery · 58
PDF
Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo
2016 · James E. Dowling, Marat Alimzhanov, et al. · ACS Medicinal Chemistry Letters · 54
Bidirectional Regulation of Kainate Receptor Surface Expression in Hippocampal Neurons
2008 · Stéphane Martin, Tristan Bouschet, et al. · Journal of Biological Chemistry · 46
PDF
Chronic Hypoxia down-Regulates Tight Junction Protein ZO-2 Expression in Children with Cyanotic Congenital Heart Defect
2015 · Emma L. Jenkins, Massimo Caputo, et al. · ESC Heart Failure · 10
PDF
Latent profiles of maternal disrupted communication: Relations to affect and behaviour in early infancy
2022 · Jennifer E. Khoury, Molly Cunningham, et al. · British Journal of Developmental Psychology · 5
PDF
Abstract 4108: Preclinical evaluation of half-life extended Affimer® biotherapeutics targeting the PD-L1 pathway
2019 · Amrik Basran, Emma Jenkins, et al. · Cancer Research · 2
Abstract 4108: Preclinical evaluation of half-life extended Affimer® biotherapeutics targeting the PD-L1 pathway
2019 · Amrik Basran, Emma Jenkins, et al. · Clinical Research (Excluding Clinical Trials) · 1
Caregiver Satisfaction with Anxiety Treatment for Autistic Youth: A Mixed Methods Examination
2026 · Wood, Jeffrey J., Marklin, Marika, et al. · UNC Libraries
Data from Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
2023 · Barry R. Davies, Nin Guan, et al.
Supplementary Figures 1-5 from Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
2023 · Barry R. Davies, Nin Guan, et al.
Abstract 1866: Pharmacokinetics and biodistribution of formatted Affimer® biotherapeutics targeting PD-L1
2021 · Estelle Adam, Emma Jenkins, et al. · Cancer Research
Abstract 2248: Generation and formatting of a bispecific Affimer® biotherapeutic for the inhibition of the LAG-3 and PD-L1 pathway
2019 · Amrik Basran, Emma Jenkins, et al. · Cancer Research
Abstract 2248: Generation and formatting of a bispecific Affimer® biotherapeutic for the inhibition of the LAG-3 and PD-L1 pathway
2019 · Amrik Basran, Emma Jenkins, et al. · Clinical Research (Excluding Clinical Trials)
Abstract 5553: Monotherapy efficacy of catalytic and allosteric inhibitors of AKT in breast cancer models with AKT1E17K mutations
2014 · Barry R. Davies, Nin Guan, et al. · Cancer Research
Abstract C274: FGF receptor mutations and fusions are therapeutic targets for inhibition by AZD4547.
2013 · Christopher R. Denz, Nin Guan, et al. · Molecular Cancer Therapeutics
Abstract 3133: Identification and functional validation of novel genetically-linked breast cancer targets through pooled gain-of-function screening.
2013 · Krishna Vasudevan, Axel Hernandez, et al. · Cancer Research
Works count: 18
Citation count: 490
H-index: 6
I10-index: 6
Year
Topic
Type